Paradigm Biocapital Advisors LP Uro Gen Pharma Ltd. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,216,084 shares of URGN stock, worth $103 Million. This represents 2.65% of its overall portfolio holdings.
Number of Shares
4,216,084Holding current value
$103 Million% of portfolio
2.65%Shares
1 transactions
Others Institutions Holding URGN
# of Institutions
171Shares Held
38.4MCall Options Held
2.66MPut Options Held
613K-
Rtw Investments, LP New York, NY4.54MShares$111 Million1.19% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77.6 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.53MShares$61.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.5 Million0.21% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$53.4 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $553M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...